Platelet-Endothelial Cell Adhesion Molecule-1 (PECAM-1), a transmembrane glycoprotein involved in leukocyte transmigration, represents a good target for endothelial drug delivery, e.g., using antibody-directed nanocarriers (anti-PECAM/NCs). Although endothelial cells do not internalize PECAM antibodies, PECAM-1 engagement by multivalent anti-PECAM conjugates and nanocarriers causes endocytosis via non-classical CAM-mediated pathway. We found that endothelial uptake of multivalent anti-PECAM complexes is associated with PECAM- 
4 which typically operate in endothelial cells, 15, 16 permitting intracellular drug delivery of reporter and therapeutic agents. 12, 14, 17, 18 CAM-mediated endocytosis requires signaling via Rho-dependent kinase ROCK 15, 19 and actin stress fiber formation, 15, 19 suggesting signaling from PECAM-1 to the cytoskeleton upon multivalent engagement of its extracellular domain. This seems somewhat similar to the central role played by Rho GTPases in the cytoskeletal changes that take place in endothelium upon multivalent attachment of leukocytes to endothelial CAMs, which regulate the assembly of actin stress fibers accompanied by an increase in endothelial permeability 20 . However, it is unknown whether PECAM-1 engagement by leukocytes induces Rho activation.
These and some other functions of PECAM-1 are associated with rearrangements of the cellular cytoskeleton, [21] [22] [23] [24] [25] [26] [27] but the mechanisms that mediate these events are not well understood.
It is likely that PECAM-1 cytoplasmic domain is required to relay signals from its extracellular domain ("outside-in" signaling). For instance, reversible phosphorylation/de-phosphorylation of tyrosine residues 663 and 686 within an Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) in the PECAM-1 cytoplasmic tail has been associated to endothelial signaling, cell recognition, permeability barrier function, and flow sensing. 24, 25, 28, 29 However, the role of the cytoplasmic tail in regulating PECAM-1 signaling and interactions with the endothelial cytoskeleton during CAM-endocytosis, which are critical for PECAM-1-targeted drug delivery into the endothelium, remains unknown.
In this study we explored the role of the PECAM-1 cytosolic domain in actin reorganization required for CAM-mediated endocytosis of anti-PECAM/NCs. We demonstrated that engagement of PECAM-1 by multivalent anti-PECAM complexes, but not monomolecular anti-PECAM, induced PECAM-1 tyrosine phosphorylation in endothelial cells. Using REN cells
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(an endothelial-like cell line derived from human mesothelioma that lacks native PECAM-1 21, 30 ) transfected with either wild-type PECAM-1 or a series of PECAM-1 cytosolic domain mutants, 9, 22 ,31-33 we identified PECAM-1 cytosolic amino acid Y686 as critical for signaling leading to RhoA activation, actin stress fiber formation, and internalization of anti-PECAM/NCs.
Importantly, these events leading to intracellular transport of anti-PECAM/NCs by CAMmediated endocytosis operated in endothelial cells in vitro and in vivo without disruption of the permeability barrier, indicating the safety of this approach for endothelial drug delivery purposes.
Materials and Methods

Antibodies and reagents. Monoclonal antibodies to human and mouse PECAM-1 were mAb62
(a gift of Dr. Nakada, Centocor, Malvern, PA) and 4G6 34 , and Mec13.3 (Santa Cruz Biotechnology, Santa Cruz, CA), respectively. Mouse monoclonal anti-phospho tyrosine-HRP (PY99) was from Santa Cruz Biotechnology. Rabbit anti-VE cadherin H72 was from Santa Cruz Biotechnology (Santa Cruz, CA). Secondary antibodies were from Jackson ImmunoResearch (West Grove, PA). Alexa Fluor 594 phalloidin was from Molecular Probes (Eugene, OR). FITClabeled 100 nm diameter polystyrene latex microspheres were from Polysciences (Warrington, PA). Rho activation assay kit was purchased from Upstate (Lake Placid, NY). All other reagents were from Sigma-Aldrich (St. Louis, MO).
Cell lines. Pooled human umbilical endothelial cells (HUVEC; Cambrex Corporation, East
Rutherford, NJ) were maintained in culture and seeded for experiments as described. 15 The human mesothelioma REN cells utilized in this work, either those which do not express
For personal use only. on . by guest www.bloodjournal.org From 6 PECAM-1, or those stably transfected with human wild-type PECAM-1 (RhP) or mutant PECAM-1 isoforms, have been previously described. 9, 22, [31] [32] [33] Briefly, REN cells transfectants expressing mutant PECAM-1 were ( Figure 3A ): ∆CD, lacking the entire PECAM-1 cytoplasmic domain; ∆11-16 and ∆15-16, in which these specific exons have been deleted; and Y663F or Y686F, in which tyrosine residues 663 or 686 were changed to phenylalanine.
Preparation of multivalent anti-PECAM complexes. Multivalent anti-PECAM mAb62
conjugates (~290 nm in diameter) were prepared by crosslinking biotinylated anti-PECAM with streptavidin (90% unlabeled, 10% rhodamine labeled) as described. 12, 17 Multivalent nanocarriers were prepared by coating anti-PECAM mAb62 on the surface of FITC-labeled 100 nm diameter polystyrene beads by surface absorption as in our prior works. 14, 15 For in vivo experiments, radiolabeled anti-PECAM/NCs contained a mix of anti-PECAM Mec13.3 and 125 I-IgG at 95:5 molar ratio. 35 The effective diameter of anti-PECAM/NCs determined by dynamic light scattering after sonication to prevent particle aggregation, was ~200 nm.
PECAM-1 expression. Total PECAM-1 expression levels were determined from cell lysates of confluent REN or PECAM-1-transfected REN cells by western blot, using 10 µg total cell protein electrophoresed on a reducing 6% polyacrylamide gel, and then transferred to polyvinylidene difluoride (PVDF) membranes and blotted with mouse anti-human PECAM-1 mAb62 and horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody. PECAM-1 protein bands were quantified by densitometry using computer-assisted image analysis, and the results were corrected to β-actin levels, used as a loading control. Cell surface PECAM-1 was immunostained for fluorescence microscopy and quantified by fluorescence activated cell sorting was performed from total proteins separated on a 4-15% polyacrylamide gel, and protein bands were revealed using either HRP-mouse monoclonal anti-phospho tyrosine (anti-pY) and goat polyclonal anti-PECAM followed by HPR-labeled anti-goat IgG. Activation of Rac by anti-PECAM/NCs in REN cells was assessed using a commercial pull-down kit (Rho activation assay kit; Upstate, Lake Placid, NY) which employs immunoprecipitation of activated Rho followed by western blot analysis, according to the manufacturer's protocol. Activated Rho was normalized to total Rho in the corresponding cell lysate for each treatment.
Endocytosis of anti-PECAM/NCs, RhoA recruitment and cytoskeleton re-arrangements.
Confluent REN cells expressing wild-type PECAM-1 (RhP) or mutant PECAM-1 isoforms were incubated at 37°C for the indicated periods of time with anti-PECAM/NCs, either in control medium or medium containing 3 mM amiloride (an inhibitor of CAM-mediated endocytosis).
Cells were washed, fixed in cold 2% paraformaldehyde, and stained with Texas red goat antimouse IgG to label non-internalized, surface located anti-PECAM/NCs. The samples were mounted on glass slides with Mowiol, and analyzed with a Nikon Eclipse TE2000-U TNFα (5 µg per mouse) served as a positive control for pulmonary edema. Three hours postinjection, animals were sacrificed and the radioactivity in lungs and blood isolated from the retro-orbital plexus was measured to calculate BSA lung-to-blood ratio.
All animal studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals and were approved by the University of Pennsylvania IACUC committee.
Statistics. Unless otherwise stated, the data were calculated as the mean ± standard deviation (SD), where statistical significance was determined by Student's t-test.
Results
Multivalent engagement of PECAM-1 induces tyrosine phosphorylation in endothelial cells
Endothelial cells do not internalize anti-PECAM antibodies, but efficiently internalize multivalent anti-PECAM complexes via CAM-mediated endocytosis, 12, 14, 19 a process induced by PECAM-1 cross-linking leading to actin remodeling. 15 To explore PECAM-1 signaling mechanism associated to CAM-mediated endocytosis, we first examined phosphorylation of PECAM-1 cytoplasmic domain in response to multivalent engagement by anti-PECAM conjugates. As shown in Figure 1 , incubation of endothelial cells (HUVEC) with multivalent anti-PECAM conjugates at 37°C, but not at 4°C, caused approximately 5-fold elevation of PECAM-1 tyrosine phosphorylation, implicating tyrosine residues in PECAM-1 cytoplasmic domain in signaling for CAM-mediated endocytosis. In contrast, non-conjugated anti-PECAM antibodies, which are known not to induce endocytosis, 12 did not cause appreciable PECAM-1 tyrosine phosphorylation ( Figure 1 ).
Role of PECAM-1 cytosolic domain in endocytosis of multivalent anti-PECAM/nanocarriers
To identify motifs in the cytosolic tail of PECAM-1 that are involved in signaling during CAM-mediated endocytosis, we used multivalent anti-PECAM/NCs produced by coating anti-PECAM onto FITC polystyrene spheres. Uniform, inert and intrinsically fluorescent multivalent anti-PECAM/NCs better serve mechanistic studies 15 than heterogeneous and polymorphous unlabeled anti-PECAM conjugates. 14 To be able to dissect PECAM-1 molecular domains responsible for signaling, we utilized a model consisting on human mesothelioma REN cells stably transfected to express different PECAM-1 mutants. 22 REN cells derived from human mesothelioma represent an appropriate model for these studies, since they express some surface antigens common to endothelial cells, and adopt a similar "cobblestone" morphology in culture. 21, 22, 30 Importantly, REN cells lack native PECAM-1 30 that would inevitably confuse the induced responses, yet both PECAM-1 distribution ( Figure S1A ) and associated signaling processes similar to endothelial cells are reconstituted after PECAM-1 expression in REN cells. 32 Consistent with our previous results in endothelial cells, 15 anti-PECAM/NCs were rapidly internalized at 37°C by REN cells expressing full-length PECAM-1 (RhP), with half-time for maximal endocytosis <30 min ( Figure 2A ). Internalization was inhibited by amiloride (60.5%±9.2 of the control level, Figure 2B ), a pharmacological inhibitor of sodium/proton exchanger proteins (e.g., NHE-1) involved in CAM-mediated endocytosis by HUVEC.
15,19
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Anti-PECAM/NCs induce Rho activation and recruitment to nanocarrier binding sites in the plasmalemma
It has been proposed that multivalent engagement of PECAM-1 can stimulate Rhodependent kinase ROCK, an effector of the small GTPase RhoA. 15 To examine whether 
Tyrosine 686 of PECAM-1 is required for remodeling of the actin cytoskeleton induced by anti-PECAM/NCs
RhoA regulates actin cytoskeleton reorganization into stress fibers 36 and filamentous actin inhibitors affect endocytosis of anti-PECAM/NCs. 15 To test whether PECAM-1 cytosolic domain is required for these actin rearrangements, REN cells expressing diverse PECAM-1 isoforms were incubated either in the absence or presence of anti-PECAM/NCs for 15 minutes at 37°C, followed by labeling filamentous actin with fluorescent phalloidin. Anti-PECAM/NCs did not bind to and had no effect on the actin cytoskeleton in REN cells lacking PECAM-1, where Actin cytoskeletal reorganization and contractility mediated by Rho GTPase can potentially disrupt intercellular junctions and reduce endothelial barrier function. 37 In theory, actin rearrangement induced by anti-PECAM/NCs in cultured RhP cells used in this work, similar to those observed in HUVEC in our prior studies, 15, 19 could also lead to cellular contraction and detrimental consequences on the endothelial permeability. In some pathological
For Secondly, we studied endothelial targeting and effects of anti-PECAM/NCs on the vascular permeability in mice. Both anti-PECAM/NCs and non-targeted control IgG/NCs were rapidly eliminated from blood (and 2.0±0.7 and 3.6±0.2 % ID/g of blood 30 min post-injection, respectively), in part due to uptake by the reticuloendothelial system in liver and spleen (Table   1 ). However, anti-PECAM/NCs, but not IgG/NCs accumulated in the lungs specifically (89.8±13.8 vs 10.2±1.1 % ID/g, Table 1 ). Indeed, lung-to-blood ratio (localization ratio, LR) of anti-PECAM/NCs vs control IgG/NCs was 107.8±29.7 vs 2.9±0.3 (Table 1) For personal use only. on October 23, 2017. by guest www.bloodjournal.org From Anti-PECAM conjugates and nanocarriers are transported from the endothelial surface to intra-endothelial vesicular compartments via a non-classical CAM-mediated endocytosis. 14, 15, 17, 42 This pathway is induced by multivalent engagement of endothelial PECAM-1 and requires actin re-organization into stress fibers, which depend on the Rho effector ROCK. 14, 15, 17, 42 However, the molecular regulation of these events, critically important for intracellular drug delivery, remains unknown.
In this study, we found that multivalent engagement of PECAM-1 by anti-PECAM conjugates or nanocarriers induced PECAM-1 tyrosine phosphorylation, RhoA recruitment to nanocarrier binding sites at the plasmalemma, and RhoA activation and actin polymerization into stress fibers, leading to endocytosis of anti-PECAM carriers both in cell cultures and pulmonary endothelium in vivo, without affecting the endothelial permeability barrier. Truncation of PECAM-1 cytosolic domain and point mutations of potential signaling residues located in this domain revealed a critical role for tyrosine 686 in the signaling regulating these events.
PECAM-1 tyrosine phosphorylation is involved in diverse pathways of cellular stimulation. 21 ,27,43 Endothelial PECAM-1 becomes phosphorylated in response to shear stress 26, 44 and by exposure to hypo-or hyperosmotic media causing cell deformation. 26 Wound-induced cell migration also stimulates PECAM-1 tyrosine phosphorylation 25 in endothelial cells, and PECAM-1 cross-linking in T lymphocytes leads to tyrosine phosphorylation. 45 Interestingly, the two ITIM motifs of PECAM-1 tyrosine 663 and 686 are involved in these events. 25, 28, 29 However, only PECAM-1 tyrosine 686 has a detectable signaling function in mediating CAM endocytosis of anti-PECAM/NCs (Figures 4 and 6 ). Although the mechanisms regulating distinct signaling through PECAM-1 tyrosine residues is unknown at present, this (Figures 2 and 4) . This indicates that CAM-mediated endocytosis regulated by PECAM-1 phosphorylation requires RhoA signaling as a downstream molecular switch to turn on or off actin signal transduction. Rho proteins 47 have been found to regulate actin cytoskeleton, cell adhesion, endocytosis, and vesicular trafficking in endothelial cells. 36 Particularly, Rho activation has been associated to numerous processes involving PECAM-1, including regulation of cell-cell and cell-matrix interactions, 48 cytoskeletal changes induced by mechanical factors, 21, 26, 27, 49, 50 and leukocyte transmigration in vivo. [1] [2] [3] [4] [5] 20, 51 Conceivably, PECAM-1 interaction with the cytoskeleton may regulate these endothelial functions. [21] [22] [23] [24] [25] [26] [27] 52, 53 In support of this notion, PECAM-1 associates physically and functionally with the underlying cytoskeleton: ~20% to 30% endothelial PECAM-1 has been found in Tritoninsoluble cytoskeleton fractions, 28,54 which increased to ~65% during cell migration. 28 The catenins are likely candidates linking PECAM-1 and the actin cytoskeleton, yet this has not been established with certainty. 27,55 Perhaps PECAM-1 may also interact with the actin cytoskeleton through the RhoA, as shown in Figure 5C . pathway. 56 However, in our studies in transfected REN cells and HUVEC ( Figure S1 ), anti-PECAM and anti-PECAM/NCs locate to junctional and luminal areas on the cell surface, and we could not establish whether one of these fractions is preferentially internalized, since intracellular anti-PECAM/NCs traffic to perinuclear endo-lysosomes. 17, 42 It is plausible that PECAM-1 engagement by anti-PECAM Ab62 (known to inhibit PECAM-1 homophilic interaction 5 ) disassembles PECAM-1 dimers at the cell-cell border causing the molecule to re-distribute to the luminal surface. However, we traced anti-PECAM/NCs 42 (not PECAM-1), and whether internalized PECAM-1 recycles to the plasmalemma from nascent invaginations is unknown.
Interestingly, a related molecule which also mediates CAM endocytosis upon multivalent engagement by nanocarriers (ICAM-1), does not traffic with anti-ICAM/NCs to lysosomes, but rather recycles to the plasmalemma after internalization. 35 Anti-PECAM/NCs specifically targeted vascular endothelium in vivo (Table 1) , and primarily accumulated in the pulmonary vasculature, which represents 30% of the body 57, 58 The relevance of endothelial targeting by anti-PECAM/NCs for drug delivery is reflected by the fact that these particles are internalized by pulmonary endothelium in vivo ( Figure 7C ), without disrupting the vascular permeability ( Figure 7D ), similarly to cultured endothelial cells ( Figure 7A and B) . This is somewhat unexpected since the integrity of endothelial junctions has been shown to be compromised by vascular stress in PECAM-1-deficient mice. [59] [60] [61] [62] [63] In addition, activation of RhoA increases actin-myosin contractility, leading to opening of intercellular junctions, 37 and thus disruption of the endothelial barrier function. In contrast to
anti-PECAM/NCs, anti-PECAM-1 F(ab')2 increases transport of 125 I-albumin across endothelial junctions, both in cultured cell and in mice. 2 It is conceivable that binding of nano-scale PECAM-1 ligands permissive of CAM-mediated endocytosis favors intracellular vesicular transport, in contrast to non-internalizable anti-PECAM, its fragments, or leukocytes with diameter on the order of 10 microns which induce opening of inter-cellular junctions.
Taken together with the lack of edema and other adverse effects in numerous animal studies documenting the therapeutic effects of anti-PECAM conjugates with antioxidant drugs, 17, 18 present results indicate that nanocarriers directed to PECAM-1 represent an attractive platform for non-damaging intra-endothelial drug delivery. Further elucidation of the molecular mechanisms involved in regulation of this process will help to better define potential utility and limits of this strategy, as well as natural role of PECAM-1 in endothelial physiology and pathology.
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